Samlyn Capital, LLC 13D and 13G filings for Corvus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 1:53 pm Purchase |
2024-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS |
Samlyn Capital, LLC | 6,667,105 9.800% |
403,347 (+6.44%) |
Filing |
| 2024-08-01 9:18 pm Sale |
2024-08-01 | 13G | Corvus Pharmaceuticals, Inc. CRVS |
Samlyn Capital, LLC | 6,263,758 9.990% |
-4,226 (-0.07%) |
Filing |
| 2024-05-13 4:52 pm Purchase |
2024-05-01 | 13G | Corvus Pharmaceuticals, Inc. CRVS |
Samlyn Capital, LLC | 6,267,984 9.990% |
3,771,725 (+151.10%) |
Filing |
| 2024-02-14 1:31 pm Purchase |
2023-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS |
Samlyn Capital, LLC | 2,496,259 5.100% |
2,496,259 (New Position) |
Filing |